A cFLIP-flop switch for senolysis
Authors
- D.N.Y. Fan
- C.A. Schmitt
Journal
- Nature Cancer
Citation
- Nat Cancer 3 (11): 1279-1281
Abstract
Persistent senescent cancer cells have tumor-promoting potential, making their selective elimination a prime therapeutic objective. The death receptor inhibitor cFLIP has now been shown to counter the susceptibility of senescent cells to DR5-mediated extrinsic apoptosis, which can be therapeutically exploited.